Who is Veradermics, and why is its pill in the spotlight?
Veradermics is a dermatology-focused biotech company that recently became a major talking point in the hair regrowth medication world. Founded by dermatologists and listed on the New York Stock Exchange as MANE, the company is developing VDPHL01, an oral hair loss pill designed for men and women with pattern hair loss. The drug is based on minoxidil, the same active ingredient in topical Rogaine, but formulated as an extended release minoxidil tablet that slowly delivers the drug into the bloodstream over time. What makes VDPHL01 stand out is its potential to be the first FDA‑approved non‑hormonal oral hair loss pill, and the first new male pattern baldness treatment in pill form in close to 30 years. That would put it alongside, and in some ways against, long‑standing options like topical minoxidil and finasteride tablets.
Inside the VDPHL01 trial: how much new hair did men actually grow?
In the pivotal Phase 2/3 Study 302, researchers enrolled 519 men with mild‑to‑moderate male pattern hair loss and randomly assigned them to once‑daily VDPHL01 (8.5 mg), twice‑daily VDPHL01, or placebo. After six months, men on the pill gained an average of about 30.3 to 33 non‑vellus (thicker, visible) hairs per square centimetre of scalp, compared with only 7.3 additional hairs in the placebo group. Visible improvement started early: statistically significant gains were seen by month two, the first measured time point. Patient satisfaction was high. Around 79.3% of men taking VDPHL01 once daily and 86.0% on twice‑daily dosing reported better hair coverage, versus 35.6% on placebo. Nearly half of once‑daily users and more than half on twice‑daily treatment rated their improvement as moderate or marked. For an oral hair loss pill, these are considered robust, clinically meaningful results over a relatively short six‑month period.
How extended-release oral minoxidil differs from today’s treatments
Minoxidil has been used for decades as a topical solution or foam, and as low‑dose generic oral tablets prescribed off‑label for hair loss. Traditional oral minoxidil is an immediate‑release medicine originally approved for high blood pressure, and higher doses can cause side effects such as fluid retention and, in rare cases, heart‑related problems. VDPHL01 aims to improve on this by using a gel‑matrix extended-release minoxidil design. The tablet slowly releases minoxidil to maintain levels above a “minimum hair growth threshold” without sharp peaks, which may lower the risk of side effects. In the 302 trial, overall side effects were similar to placebo, with no treatment‑related serious adverse events and no cardiac events of special interest reported. If this safety profile holds up in further studies and real‑world use, VDPHL01 could offer a more predictable, dermatologist‑designed version of oral minoxidil, rather than the improvised low‑dose regimens currently used off‑label.
Regulation, competition and when Malaysians might see VDPHL01
Despite the strong data, VDPHL01 is not on pharmacy shelves yet. Veradermics has completed this first pivotal trial and has already fully enrolled a second Phase 3 male study, called Study 304, with results expected in the second half of 2026. The company will need to submit these findings to the U.S. Food and Drug Administration for review. Only after a potential U.S. approval could it pursue approvals in other markets, such as Malaysia, through local regulators like the National Pharmaceutical Regulatory Agency (NPRA). Even if everything goes smoothly, Malaysian men are likely several years away from accessing this specific oral hair loss pill. By then, VDPHL01 will face strong competition: established topical minoxidil brands, generic finasteride, off‑label oral minoxidil prescribed by doctors, and online telemedicine platforms already selling hair regrowth medication packages. Pricing, patent protection through at least 2043 in the U.S., and whether generics can copy the extended‑release design will also shape how widely it is adopted.
What it really means for men in Malaysia: benefits and limits
For Malaysian men with male pattern baldness, VDPHL01—if eventually approved locally—could become an attractive option, especially for those who dislike messy topical solutions or are wary of finasteride’s hormonal side effects. The main benefits suggested by the trial are solid hair density gains, relatively fast onset within two months, once‑ or twice‑daily convenience, and a safety profile so far similar to placebo, without heart‑related safety signals in the study. However, this is not a miracle cure. The pill improved hair growth, but it did not fully restore teenage‑level density, and responses varied between individuals. As with other male pattern baldness treatment options, ongoing use will probably be needed to maintain results. Men with existing heart disease, uncontrolled blood pressure, or on multiple medications will still need careful evaluation by a doctor. When it eventually arrives, VDPHL01 should be seen as a promising new tool in the toolbox—not a guaranteed fix for every case of thinning hair.
